|Multi-target kinase inhibitor, inhibits VEGFR, PDGFR, and FGFR|
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
Related Biological Data
|Description||Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively.|
|IC50||10 nM||30 nM||47 nM||84 nM||74 nM|
|Cas No.||635702-64-6||SDF||Download SDF|
|Synonyms||Pazopanib, Votrient, GW786034B, GW 786034, GW-786034|
|Solubility||Soluble in DMSO||Storage||Desiccate at -20°C|
|Shipping Condition:||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
View Related Products By Research Topics
Due to recent approval for the treatment of STS, a retrospective analysis of pazopanib in STS has been conducted.
The acceptable dose of oral pazopani is to be identified in order to investigate AMD.
Pazopanib is a substrate for ATP-binding cassette family transporter that exhibits anti-gynecological cancer activity in combination with metronomic topotecan.
Due to a progression-free survival observed in previous studies, pazopanib and sunitinib have been assessed for efficacy and safety in a randomized trial.
The dual pathway blockade by tyrosine kinase inhibitors was examined.
Pazopanib is a potent and selective second generation multi-targeted receptor tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-kit tyrosine kinases. It is involved in inhibiting signaling pathways, angiogenesis, and cell proliferation. Pazopanib exhibited excellent anti-angiogenic and anti-tumor activity and synergism was observed in combination with chemotherapeutic drugs in several mouse models of a variety of tumors, accompanied by desirable pharmacokinetics and oral bioavailability. It inhibits the intracellular tyrosine kinase portion of all the VEGFR subtypes, and exhibits distinct pharmacokinetic and toxicity profiles compared with other agents among VEGF signaling pathway inhibitors. Recent studies elucidated its importance of signaling cascades related to angiogenesis in the management of RCC.
Sonpavde G, Hutson T E. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Current oncology reports. 2007; 9(2): 115 - 119.
Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences. 2006; 103(51): 19478 - 19483.